Novo Nordisk A/S(NYSE : NVO)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||1.49%||165.63||0.7%||$1350.47m|
|LLY||Eli Lilly & Co.||1.50%||326.36||1.1%||$1083.66m|
|BMY||Bristol-Myers Squibb Co.||1.59%||71.65||1.0%||$784.94m|
|MRK||Merck & Co., Inc.||1.12%||88.53||0.7%||$718.32m|
|ALNY||Alnylam Pharmaceuticals, Inc.||-0.74%||195.34||8.2%||$215.79m|
|GBT||Global Blood Therapeutics, Inc.||0.00%||68.48||5.4%||$191.16m|
|IDXX||IDEXX Laboratories, Inc.||3.40%||348.13||3.9%||$190.55m|
|HZNP||Horizon Therapeutics Plc||1.56%||65.26||5.4%||$176.35m|
|ATXI||Avenue Therapeutics, Inc.||21.81%||14.02||0.0%||$169.69m|
|SRPT||Sarepta Therapeutics, Inc.||0.32%||110.30||12.4%||$137.18m|
Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in BagsvÃ¦rd, Denmark.